Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2022 01/14/2022 01/18/2022 01/19/2022 01/20/2022 Date
4.41(c) 4.44(c) 4.22(c) 4.26(c) 4.14(c) Last
1 683 393 990 234 938 927 951 226 605 443 Volume
-1.34% +0.68% -4.95% +0.95% -2.82% Change
More quotes
Estimated financial data (e)
Sales 2021 38,2 M 43,3 M 43,3 M
Net income 2021 -56,0 M -63,4 M -63,4 M
Net cash position 2021 172 M 195 M 195 M
P/E ratio 2021 -7,71x
Yield 2021 -
Sales 2022 48,6 M 55,0 M 55,0 M
Net income 2022 -64,9 M -73,5 M -73,5 M
Net cash position 2022 93,0 M 105 M 105 M
P/E ratio 2022 -6,84x
Yield 2022 -
Capitalization 451 M 510 M 510 M
EV / Sales 2021 7,29x
EV / Sales 2022 7,36x
Nbr of Employees 153
Free-Float 97,2%
More Financials
Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28... 
More about the company
Ratings of Affimed N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AFFIMED N.V.
01/06AFFIMED N : Announces Completion of Enrollment in REDIRECT, the Registration-Directed Stud..
PU
01/06Affimed Completes Enrollment in Phase 2 Lymphoma Trial; Gets FDA Nod for Another AFM13 ..
MT
01/06Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study..
GL
01/06Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed ..
CI
01/05Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd Ame..
AQ
2021AFFIMED N : Press Release dated December 9, 2021 - Form 6-K
PU
2021Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-De..
CI
2021Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymph..
AQ
2021Affimed Starts Patient Enrolment for Study to Evaluate Combination Treatment Targeting ..
MT
2021Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM..
AQ
2021Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engage..
CI
2021AFFIMED N : Investor Day
PU
2021Health Care Stocks Finishing Mixed This Afternoon
MT
2021Health Care Stocks Drifting Near Unchanged Mark Monday
MT
More news
News in other languages on AFFIMED N.V.
01/06Affimed N.V. annonce la fin du recrutement dans Redirect, l'étude dirigée par l'enregis..
2021Affimed commence à recruter des patients pour une étude visant à évaluer une combinaiso..
2021Les actions du secteur de la santé terminent en demi-teinte cet après-midi
2021Les actions du secteur de la santé dérivent près de la marque inchangée lundi
2021Innate Cell Engager d'Affimed NV obtient un taux de réponse objective de 100% dans une ..
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,66 €
Average target price 11,61 €
Spread / Average Target 217%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Commercial Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.-25.00%510
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805